BioSavita Appoints James Kuo, M.D., M.B.A., Chairman and Chief Executive Officer

September 27, 2012

BioSavita, Inc. announced today that its board has appointed James Kuo, M.D., M.B.A., Chairman and Chief Executive Officer. He plans to lead the company’s growth through development of its portfolio of biosimilar products and additional corporate partners for its Twin Cassette® yeast expression technology, which allows rapid production of fully functional antibodies in secreted form.

Dr. Kuo has over 20 years of life science industry experience as a venture

capitalist, pharmaceutical

business development executive and senior manager of private and publicly-traded biotech companies. Prior to joining BioSavita, Dr. Kuo served as Chairman and Chief

Executive Officer of Adeona Pharmaceuticals, a publicly-traded Michigan biotech company. Prior

to Adeona, he served as Chairman and Chief Executive Officer of BioMicro Systems, a

genomic tools company. Dr. Kuo is also a founder and served as Chief Executive Officer of Discovery Laboratories, a publicly-traded company commercializing surfactant-based respiratory therapeutics. He has been Associate Director of Licensing and Development at Pfizer and Vice President of Business Development at Myriad Genetics. Dr. Kuo was Managing Director of Venture Analysis at HealthCare Ventures, a venture capital firm with $378 million in funds under management. He is Chairman of the Board at MSK Pharma, a company developing pharmaceutical therapies for pain and musculoskeletal diseases. He is also Chairman of the Board at Monarch Labs, a company commercializing

medical devices for wound care. Dr. Kuo received his M.D. from the University of Pennsylvania School of

Medicine and his M.B.A. from the Wharton School of Business. He received his B.A. in molecular biology from Haverford College.

“On behalf of the boardof directors, I welcome Jim’s appointment as Chairman and Chief Executive Officer,” stated Joseph DeAngelo, BioSavita’s board director. “His past experience shows that he can inject more commercial focus to our biosimilar pipeline and establish more partnerships for our high-throughput yeast

expression cassette technology.”

“It is a pleasure to join a company that is seeking to develop a portfolio of biosimilars, which potentially offers a more rapid regulatory pathway to commercial approval. I am excited that BioSavita has already established five corporate collaborations to validate its Twin Cassette® yeast expression technology,” stated Dr. Kuo.